Press Releases Adicet Bio, Inc.

Equities

ACET

US0070021086

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
1.68 ^USD	-7.18%		-13.85%	-11.11%

Apr. 22	Adicet Bio, Inc. Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the ASGCT 27th Annual Meeting	CI
Mar. 26	North American Morning Briefing : Markets Steady -2-	DJ

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Adicet Bio Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the American Society of Gene and Cell Therapy 27th Annual Meeting	Apr. 23	AQ
Adicet Bio Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting	Apr. 22	BU
Adicet Bio to Participate in 2024 Canaccord Genuity Horizons in Oncology Virtual Conference	Apr. 08	BU
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)	Mar. 28	BU
Adicet Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress	Mar. 19	BU
Adicet Bio to Participate in a Fireside Chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference	Mar. 11	BU
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)	Feb. 29	BU
Adicet Bio to Participate in a Fireside Chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference	Feb. 05	BU
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)	Jan. 31	BU
Adicet Bio, Inc. Announces Closing of $98 Million Public Follow-On Offering and Exercise in Full of the Underwriters Option to Purchase Additional Shares	Jan. 26	AQ
Adicet Bio, Inc. Announces Closing of $98 Million Public Follow-On Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares	Jan. 25	BU
Adicet Bio, Inc. Announces Pricing of Public Offering	Jan. 22	BU
Adicet Bio, Inc. Announces Proposed Public Offering	Jan. 22	BU
Adicet Provides Corporate Update and Highlights Strategic Priorities for 2024	Jan. 04	BU
Adicet Bio to Host Conference Call to Provide Updates on its Clinical Pipeline and Corporate Outlook	Jan. 03	BU
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)	Dec. 29	BU
Adicet Bio Highlights ADI-001 Expansion, Persistence and Pharmacodynamic Profile from Ongoing Phase 1 Study at the 65th American Society of Hematology Annual Meeting	Dec. 11	AQ
Adicet Bio Highlights ADI-001 Expansion, Persistence and Pharmacodynamic Profile from Ongoing Phase 1 Study at the 65th American Society of Hematology (ASH) Annual Meeting	Dec. 10	BU
Purcell & Lefkowitz LLP Announces Shareholder Investigation of Adicet Bio, Inc. (NASDAQ: ACET)	Dec. 04	PR
Adicet Reports Third Quarter 2023 Financial Results and Provides Business Updates	Nov. 08	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Adicet Bio, Inc.

Equities

ACET

US0070021086

Press Releases

Filters